Navigation Links
STEMCELL Technologies Introduces a New Animal Component-Free, Serum-Free Medium for Culturing Human Mesenchymal Stem Cells
Date:4/28/2009

STEMCELL Technologies, Inc. today announced the release of MesenCult®-ACF Medium, the first defined, animal component-free (ACF) and serum-free medium for culturing human mesenchymal stem cells (MSCs).

Vancouver, B.C. (PRWEB) April 28, 2009 -- STEMCELL Technologies, Inc. today announced the release of MesenCult®-ACF Medium, the first defined, animal component-free (ACF) and serum-free medium for culturing human mesenchymal stem cells (MSCs).

MesenCult®-ACF Medium supports long-term growth of MSCs with retention of multi-lineage differentiation potential. In addition, MSCs cultured in MesenCult®-ACF Medium expand faster and show a significant reduction in hematopoietic cell contamination at early passages compared to serum-containing media.

"MesenCult®-ACF Medium is a very important addition to our product portfolio and indicates our strong interest in remaining at the cutting edge of scientific and preclinical work in the stem cell arena," says Dr. Allen Eaves, President and CEO of STEMCELL Technologies.

There is considerable interest in using mesenchymal stem cells as therapeutic agents for the treatment of a wide variety of diseases. Because of this clinical interest, there is a need to culture the cells in animal component-free culture systems, in order to minimize the risk associated with disease transmission and immune rejection of transplanted cells. The availability of MesenCult®-ACF Medium will greatly facilitate advances in efforts to assess the therapeutic relevance of mesenchymal stem cells.

Furthermore, the removal of undefined components within the medium reduces the variability traditionally associated with culture of these cells and allows for more consistent research and development work on this very important cell type.

For more information about MesenCult®-ACF Medium, please visit http://www.stemcell.com/product_catalog/hu_mesencult-acf.aspx.

Contact
Kristy Favell, MSc, Assistant Product Manager - Neural and Mesenchymal Cell Biology
STEMCELL Technologies Inc
604.668.0875

About STEMCELL Technologies
STEMCELL Technologies, a privately-owned biotechnology company, is a leader in specialty cell culture media, cell separation products and ancillary reagents for life science research. Driven by science, STEMCELL delivers over 900 products to more than 70 countries worldwide. To learn more about how STEMCELL helps to make research work, visit www.stemcell.com

###

Read the full story at http://www.prweb.com/releases/stemcelltechnologies/mesencultacf/prweb2365414.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Neuralstem Responds to New StemCells, Inc. Lawsuit
2. Neuralstem Sues StemCells, Inc. Over New Patent
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. China Medical Technologies Receives SFDA Approval for Its Bladder Cancer FISH Probe
5. Dr. Susan Weinschenk, Chief of Technical Staff and Services, Speaks on Neuro Web Design at Persuasive Technologies 2009 Conference and Voices That Matter Web Design Conference
6. China Biologic Products Completes Acquisition of 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd.
7. Waters and University of Warwick Sign Research Agreement Designed to Foster Adoption of Novel MS Technologies
8. ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canadas Ability to Deal with Biological Threats
9. Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results
10. Vertebral Technologies Receives Award for InterFuse(R) Interbody Fusion System
11. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):